BACKGROUND: Mastectomy is considered the treatment of choice in patients with ipsilateral breast tumour recurrence (IBTR) after breast-conserving surgery (BCS). PATIENTS AND METHODS: One hundred and sixty-one patients with invasive IBTR who underwent a second conservative approach were retrospectively evaluated in order to describe prognosis, determine predictive factors of outcome and select the subset of patients with the best local control. RESULTS: Fifty-seven patients (35.4%) relapsed after IBTR. Thirty-four patients (21.1%) had further in-breast recurrences and four patients (2.5%) had skin relapses. Five years cumulative incidence of local relapse was 31.4%. Twenty-four patients (17.8%, 5 years cumulative incidence) died during the follow-up. At the multivariate analysis, recurrent tumour size >2 cm was found to affect local-disease-free survival [hazard ratio (HR): 2.8, 95% confidence interval (CI) 1.2-6.2], whereas Ki-67 >or=20% and time to relapse <or=48 months were associated with disease-free survival (HR: 1.7, 95% CI 1.0-3.1, and HR: 2.1, 95% CI 1.2-3.6, respectively). Absence of oestrogen receptors affected overall survival (HR: 2.5, 95% CI 1.1-6.0). Among 64 patients with recurrent tumour <or=2 cm and time to IBTR >48 months, eight (12.8%, 5 years cumulative incidence) had further local relapses. CONCLUSIONS: Some patients with IBTR might receive a second BCS, especially when a good local control can be estimated (small recurrent tumour, late relapse), also taking into account patients' preference.
BACKGROUND: Mastectomy is considered the treatment of choice in patients with ipsilateral breast tumour recurrence (IBTR) after breast-conserving surgery (BCS). PATIENTS AND METHODS: One hundred and sixty-one patients with invasive IBTR who underwent a second conservative approach were retrospectively evaluated in order to describe prognosis, determine predictive factors of outcome and select the subset of patients with the best local control. RESULTS: Fifty-seven patients (35.4%) relapsed after IBTR. Thirty-four patients (21.1%) had further in-breast recurrences and four patients (2.5%) had skin relapses. Five years cumulative incidence of local relapse was 31.4%. Twenty-four patients (17.8%, 5 years cumulative incidence) died during the follow-up. At the multivariate analysis, recurrent tumour size >2 cm was found to affect local-disease-free survival [hazard ratio (HR): 2.8, 95% confidence interval (CI) 1.2-6.2], whereas Ki-67 >or=20% and time to relapse <or=48 months were associated with disease-free survival (HR: 1.7, 95% CI 1.0-3.1, and HR: 2.1, 95% CI 1.2-3.6, respectively). Absence of oestrogen receptors affected overall survival (HR: 2.5, 95% CI 1.1-6.0). Among 64 patients with recurrent tumour <or=2 cm and time to IBTR >48 months, eight (12.8%, 5 years cumulative incidence) had further local relapses. CONCLUSIONS: Some patients with IBTR might receive a second BCS, especially when a good local control can be estimated (small recurrent tumour, late relapse), also taking into account patients' preference.
Authors: Soo Yeon Baek; Jisun Kim; Il Yong Chung; Beom Seok Ko; Hee Jeong Kim; Jong Won Lee; Byung Ho Son; Sei-Hyun Ahn; Sae Byul Lee Journal: Breast Cancer Res Treat Date: 2022-01-30 Impact factor: 4.872
Authors: Astrid Botty Van den Bruele; Ishita Chen; Varadan Sevilimedu; Tiana Le; Monica Morrow; Lior Z Braunstein; Hiram S Cody Journal: Breast Cancer Res Treat Date: 2021-01-12 Impact factor: 4.872
Authors: Min-Young Lee; Won Jin Chang; Hae Su Kim; Ji Yun Lee; Sung Hee Lim; Jeong Eon Lee; Seok Won Kim; Seok Jin Nam; Jin Seok Ahn; Young-Hyuck Im; Yeon Hee Park Journal: PLoS One Date: 2016-09-20 Impact factor: 3.240
Authors: Soo Yeon Baek; Jisun Kim; Il Yong Chung; Beom Seok Ko; Hee Jeong Kim; Jong Won Lee; Byung Ho Son; Sei-Hyun Ahn; Sae Byul Lee Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 2.339